4-Hexynoic acid, 2-(((4-((4-methoxybenzoyl)amino)phenyl)sulfonyl)amino)-6-(4-morpholinyl)-
PG-530742 selectively inhibits certain matrix metalloproteinases that have been implicated in the cartilage degradation that occurs in osteoarthritis. By inhibiting these MMPs, it potentially limits cartilage degradation and disease progression. Studies are currently assessing the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.